-
-
-
-
-
-
-
Truist on MBX Biosciences Inc (MBX): 'We remain buyers'
-
-
-
-
-
-
-
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
-
-
-
-
-
-
-
Microbix Announces Initiation of Normal Course Issuer Bid
-
-
-
-
-
-
-
Microbix Presenting at Muskoka Capital Event
-
-
-
-
-
-
-
Microbix Launches QUANTDx™ Characterized Reference Materials
-
-
-
-
-
-
-
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Microbix Further Optimizes Capital Usage and Availability
-
1,216,209 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

